Streptomyces griseus Versus Trichoderma viride Chitinase as an Anti-inflammatory and Antifungal Agent Against Human...

Fungal pathogens represent a massive global health burden, causing over a billion infections and 1.6 million deaths annually. Prior research has shown that the limited repertoire of available antifungal medications exacerbates the threat posed by these human pathogens. While existing treatments exist, the rise of drug-resistant strains necessitates the discovery of novel, safe, and potent therapeutic agents. Chitinases, enzymes that degrade the fungal cell wall component chitin, have demonstrated significant efficacy against plant-based fungal pathogens in agricultural settings. Despite their success in phytopathology, investigations into the utility of these enzymes against fungi that infect humans remain sparse. This absence of evidence motivated the current exploration into the therapeutic potential of microbial enzymes.

This investigation evaluates the anti-inflammatory and antifungal properties of bacterial and fungal chitinases against several human pathogenic fungi. The researchers sought to compare the efficacy of Streptomyces griseus and Trichoderma viride enzymes. One primary objective involved determining whether a synergistic effect occurs when combining these two distinct microbial sources. Another goal focused on quantifying the ability of these proteins to mitigate inflammatory responses through biochemical assays. The study specifically targeted pathogens like Aspergillus fumigatus, Cryptococcus neoformans, and various Candida species. By measuring fungal growth inhibition and protein stabilization, the team aimed to establish a new pharmacological profile for these biocatalysts.

The experimental design utilized bacterial chitinase derived from Streptomyces griseus alongside fungal chitinase from Trichoderma viride. Researchers calculated the inhibition percentage of fungal growth by monitoring the reduction in the dry mass of the targeted organisms. This gravimetric approach provided a precise measure of how the enzymes disrupted the structural integrity of the fungal pathogens. To assess anti-inflammatory potential, the team employed an assay measuring the inhibition of albumin denaturation. This specific biochemical test serves as a proxy for the stabilization of proteins during inflammatory stress. The study compared the performance of individual enzymes against a combined formulation to identify potential potentiation.

The combination of bacterial and fungal chitinase yielded the highest antifungal activity across all tested human pathogenic fungi. Both chitinase sources outperformed the standard antifungal agent used as a control in the growth inhibition assays. Bacterial chitinase from S. griseus showed superior effectiveness specifically against Aspergillus fumigatus compared to the fungal variant. In contrast, both enzyme types exhibited comparable inhibitory effects when applied to Cryptococcus neoformans and Candida species. Regarding anti-inflammatory metrics, the chitinases successfully prevented 98% of albumin denaturation in the experimental model. These findings represent the first documented instance of chitinases functioning as agents to prevent protein denaturation.

These results suggest that microbial chitinases hold significant promise as dual-action therapeutic agents for human health. The high level of growth inhibition indicates that these enzymes could supplement or replace current antifungal drugs. Future research must prioritize in-vivo studies to confirm these antifungal effects within complex biological systems. Investigating the specific molecular pathways behind the 98% inhibition of albumin denaturation remains a priority for subsequent trials. The synergistic potential of combining bacterial and fungal sources offers a new strategy for treating multi-drug resistant infections. Clinical applications may eventually include topical or systemic treatments for Aspergillus, Cryptococcus, and Candida infections.